Pasireotide

Pasireotide can bind to multiple somatostatin receptor subtypes (SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5). By enhancing the agonist activity of somatostatin receptors, it inhibits the secretion of growth hormone (GH), insulin - like growth factor - I (IGF - I), and adrenocorticotropic hormone (ACTH). Pasireotide also has anti - proliferative and pro - apoptotic activities, which can inhibit the growth and proliferation of tumor cells and plays a certain role in the treatment of related tumors such as pituitary adenomas. It is applicable to the treatment of adult patients with acromegaly who cannot undergo surgery or for whom surgery is not curative, and whose condition is poorly controlled by treatment with another somatostatin analog. It can significantly reduce the levels of GH and IGF - I in patients, improve their symptoms and quality of life, such as alleviating acromegaly, hyperhidrosis, fatigue and other symptoms, and can also reduce the volume of pituitary adenomas. It is used for patients with Cushing's disease who cannot undergo pituitary surgery or have poor postoperative results. It can effectively control the level of urinary free cortisol (UFC), improve related symptoms such as blood pressure and body weight, and enhance the quality of life of patients.